Jess Hearn

Recent Posts

Gene therapy manufacturing license negotiation

Challenge A private biotech company developing gene therapy products for several orphan diseases was in the process of initiating CMC development for their pipeline products. In order to move...
Learn More

Due diligence on generic therapeutic

Challenge A private investment firm was seeking an independent reality-check on a potential investment in a pharmaceutical company that had recently in-licensed a generic therapeutic asset. The firm...
Learn More

Competitive and market landscape for CAR T-cell therapy

Challenge: A biotech company developing a platform technology to improve the safety of CAR T-cell therapies asked Alacrita to conduct a comprehensive competitive landscape to better understand the...
Learn More

New in-licensing opportunities in inflammation

Challenge A small molecule pharmaceutical incubator is using a novel and proprietary drug discovery and translational platform to develop first-in-class, small molecule therapeutics for the treatment...
Learn More

Comprehensive review of the glioblastoma (GBM) landscape

Challenge A stem cell research company had developed a target product profile (TPP) for a novel therapy for glioblastoma (GBM). The company asked Alacrita to conduct a comprehensive review of the GBM...
Learn More

Developing a Target Product Profile (TPP) for a novel gene therapy

Challenge A privately-held biotechnology company developing and exploiting a proprietary technology platform for optimizing and controlling gene therapy expression was looking to evolve its business...
Learn More

Advice for regulatory approval of a new Ancestral DNA device

Challenge Our client offered a genetic ancestry test in the form of a home kit that contained a buccal swab to collect customer DNA and an analysis service using a SNP array-based chip. Results were...
Learn More
1